

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Pharmacology and Therapeutics Advisory Committee (PTAC) Provisional recommendations 15 August 2025

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Fremanezumab for people experiencing chronic migraine, subject to Special Authority criteria	High Priority
Fremanezumab for people experiencing episodic migraine, subject to Special Authority criteria	High Priority
Tirzepatide for people with type 2 diabetes mellitus, whose blood sugar is high despite other treatments, subject to Special Authority criteria	Medium Priority
Avacopan for people with ANCA-associated vasculitis, subject to Special Authority criteria	High Priority
Inclisiran for people with heterozygous familial hypercholesterolemia, subject to Special Authority criteria	High Priority
Pembrolizumab (Keytruda) for the first-line treatment of people with unresectable advanced malignant pleural mesothelioma, subject to Special Authority criteria	*Withheld
Pembrolizumab (Keytruda) for the first-line treatment of people with unresectable advanced non-epithelioid subtypes of malignant pleural mesothelioma, subject to Special Authority criteria	*Withheld

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

[More information about the Pharmacology and Therapeutics Advisory Committee is on Pharmac's website](#)

Released 17 September 2025